Work

Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.8028

Authors: Anthony R. Mato, Jeff P. Sharman, Juliana Biondo, Mei Wu, Yong Mun, Su Young Kim, Kathryn Humphrey, Michelle Boyer, Qian Zhu, John F. Seymour

Institutions: Memorial Sloan Kettering Cancer Center, Willamette Valley Cancer Institute and Research Center, Genentech, AbbVie (United States), Roche (United Kingdom), The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032132455

Cites:

Cited by: 2

Related to: 10